MaxCyte, Inc. Signing of Strategic Platform License (5691L)
January 04 2023 - 2:00AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 5691L
MaxCyte, Inc.
04 January 2023
MaxCyte Signs Strategic Platform License with Catamaran Bio to
Support its CAR-NK Cell Therapy Programs
MaxCyte's Flow Electroporation(R) and ExPERT(TM) technologies to
be used to enhance Catamaran's TAILWIND(R) platform for novel
CAR-NK cell therapies
ROCKVILLE, MD, January 4, 2023 -- MaxCyte, Inc. , (Nasdaq: MXCT;
LSE: MXCT), a leading commercial cell-engineering company providing
enabling platform technologies to advance innovative cell-based
research, as well as next-generation cell therapeutic discovery,
development and commercialization, today announced the signing of a
strategic platform license (SPL) with Catamaran Bio, Inc. , a
biotechnology company developing novel, off the-shelf chimeric
antigen receptor (CAR)-NK cell therapies to treat a broad range of
cancers, with a primary focus on solid tumors.
Under the terms of the agreement, Catamaran obtains
non-exclusive clinical and commercial rights to use MaxCyte's Flow
Electroporation(R) technology and ExPERT(TM) platform. In return,
MaxCyte will receive platform licensing fees and program-related
revenue.
"The ability to leverage synthetic biology to engineer cell
therapies will help drive innovative solutions for solid tumor
cancer treatment. At MaxCyte, we are passionate about driving the
discovery, development and manufacturing of next-generation,
cell-based medicines to tackle complex diseases and cancer," said
Doug Doerfler, President and CEO of MaxCyte. "We are excited to
support Catamaran with the advancement of their pipeline of
differentiated CAR-NK cell therapies into and through the
clinic."
Catamaran is currently using synthetic biology and non-viral
cell engineering to develop highly potent allogeneic, cryopreserved
CAR-NK cell therapies capable of treating challenging cancers,
including solid tumors, by combining new functional attributes with
the inherent cancer-fighting properties of NK cells. The company
has developed its TAILWIND(R) platform, an integrated suite of
technologies, to engineer, expand and process NK cells into safe
and effective, off-the-shelf cell therapy products for multiple
cancer types.
MaxCyte's ExPERT(TM) instrument portfolio is the next generation
of leading, clinically-validated electroporation technology for
complex and scalable cell engineering. By delivering high
transfection efficiency, seamless scalability and enhanced
functionality, the ExPERT(TM) platform delivers the high-end
performance essential to enabling the next wave of biological and
cellular therapeutics. The Catamaran agreement is MaxCyte's 19th
SPL overall.
About MaxCyte
MaxCyte is a leading, cell-engineering focused company providing
enabling platform technologies to advance the discovery,
development and commercialization of next-generation cell
therapeutics and to support innovative, cell-based research. Over
the past 20 years, we have developed and commercialized our
proprietary Flow Electroporation(R) technology, which facilitates
complex engineering of a wide variety of cells. Our ExPERT(TM)
platform, which is based on our Flow Electroporation technology,
has been designed to support the rapidly expanding cell therapy
market and can be utilized across the continuum of the high-growth
cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The
ExPERT family of products includes: four instruments, the ATx(R),
STx(R) GTx(R) and VLx(TM); a portfolio of proprietary related
processing assemblies or disposables; and software protocols, all
supported by a robust worldwide intellectual property
portfolio.
Learn more at maxcyte.com and follow us on Twitter and LinkedIn
.
About Catamaran Bio
Catamaran Bio is developing novel, off-the-shelf chimeric
antigen receptor (CAR)-NK cell therapies designed to treat a broad
range of cancers, including solid tumors. The company's proprietary
capabilities enable it to harness the natural cancer-fighting
properties of NK cells and enhance and tailor their effectiveness
with the power of synthetic biology and innovative non-viral cell
engineering. Catamaran uses its TAILWIND(R) platform , an
integrated suite of technologies, to specifically address the
end-to-end methods of engineering, processing and manufacturing NK
cells and rapidly advance its pipeline of CAR-NK cell therapy
programs. The company's team combines experienced biopharmaceutical
leadership with founding scientists who are pioneers in NK cell
biology, engineering, manufacturing and clinical application.
Catamaran is backed by leading financial and corporate investors,
including SV Health Investors, Sofinnova Partners, Lightstone
Ventures, Takeda Ventures, Astellas Venture Management, and the UMN
Discovery Capital investment program. For more information, please
visit catamaranbio.com and follow Catamaran on LinkedIn and
@CatamaranBio on Twitter.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
US Media Relations
Spectrum Seismic Collaborative
Valerie Enes
+1 408-497-8568
valerie@spectrumscience.com
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR Adviser
Consilium Strategic Communications
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDBJMRTMTBMBRJ
(END) Dow Jones Newswires
January 04, 2023 02:00 ET (07:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024